Eosinophil

SAN DIEGO — Patients with higher eosinophil counts experienced more cardiovascular disease, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric oxide levels in a moderate to severe asthma cohort, according to a poster presented here.

BOSTON — Rhinovirus infections in children with a nascent type 2 inflammatory signature may be at greater risk for asthma, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for treating patients with COPD plus an eosinophilic phenotype, according to a GSK press release.

Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results published in The Lancet Respiratory Medicine.

Patients with mild to moderate asthma and self-reported asthma control may have elevated levels of fractional exhaled nitric oxide and eosinophils, according to a poster presented at the European Respiratory Society International Congress.

BOSTON — The impact of e-cigarette use on eosinophil and basophil counts may depend on HIV serostatus, according to a study presented at the CHEST Annual Meeting.

Sublingual immunotherapy for house dust mites improved allergic rhinitis symptoms over a 1-year period among children aged 1 to 4 years, according to results from an open-label study..

Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European Respiratory Society International Congress.

SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the American Thoracic Society International Conference.